FDA Says Bromfed-DM Wasn't Pulled for Safety or Effectiveness
Published Date: 11/18/2026
Notice
Summary
The FDA has confirmed that BROMFED-DM syrup, in all its strengths, wasn’t pulled from the market because of safety or effectiveness problems. This means generic drug makers can keep getting approval to sell their versions, as long as they follow the rules. If you rely on this cough and cold syrup, no worries—it’s staying available and safe for now!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Generic Approvals May Continue
FDA determined that BROMFED-DM syrup was not withdrawn for reasons of safety or effectiveness. As a result, FDA will not begin procedures to withdraw approval of approved abbreviated new drug applications (ANDAs) that refer to this product, and additional ANDAs referencing this listed drug may be approved if they meet legal and regulatory requirements. The listed drug is ANDA 088811 (initially approved June 07, 1985); the branded holder notified FDA of discontinuation by letter dated January 8, 2026, and a citizen petition was submitted March 26, 2026.
Product Listed as Discontinued (Not for Safety)
FDA will continue to list BROMFED-DM syrup in the Orange Book’s “Discontinued Drug Product List,” which indicates the product was discontinued from marketing for reasons other than safety or effectiveness. The branded holder informed FDA of the discontinuation on January 8, 2026, and FDA found no evidence of withdrawal for safety or effectiveness in its review.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-23351, Rulemaking To Provide That N-acetyl-L-cysteine Is Not Excluded From the Dietary Supplement Definition
The FDA wants to officially say that N-acetyl-L-cysteine (NAC) can be sold as a dietary supplement. This means companies can legally put NAC in their products without breaking the rules, as long as they follow other laws. People and businesses making or selling supplements with NAC should share their thoughts by January 19, 2027.
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
Previous / Next Documents
Previous: 2026-23413, Salerno Pharmaceuticals; Proposal To Withdraw Approval of a New Drug Application for Flolipid Suspension, 20 Milligrams/5 Milliliters and 40 Milligrams/5 Milliliters; Opportunity for a Hearing
The FDA plans to pull the approval for Salerno Pharmaceuticals' Flolipid Suspension because the company hasn’t submitted required yearly reports. Salerno has until December 18, 2026, to ask for a hearing to explain themselves. This affects anyone using or selling Flolipid and could change its availability soon.
Next: 2026-23416, Proposed Third-Party Risk Management Guidance; Extension of Comment Period
The OCC, Federal Reserve, FDIC, and NCUA want your thoughts on new rules for managing risks from outside companies that banks work with. They’ve extended the deadline to send comments from November 16 to December 16, 2026, giving everyone more time to weigh in. These changes aim to help banks better handle risks based on how risky each partner is, keeping your money safer without extra costs right now.